Repros’ Proellex Is Poised To Enter Phase III – Again
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Telapristone was put on clinical hold due to liver toxicity, but the company’s pursuit of vaginal formulation and re-analysis of the initial oral studies allowed the oral program to resume.
You may also be interested in...
Fast Track Pathway May Be ‘Poor Man’s Breakthrough’ But It Works
Most requests for the FDA’s less-heralded expedited review designation are based on Phase II or earlier data, and have a greater chance of success than requests for breakthrough designation.
Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Keeping Track: Quick Trips From Breakthrough Designation To Market
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: